Mai Jiaxi, Zhou Tingwei, Wang Chen, Ye Junrong, Chen Jiao, Wang Wen, Pan Yuanxin, Wei Yanheng, Yuan Lexin, Yang Hang, Wu Shengwei, Guo Jianxiong, Xiao Aixiang
Department of Science and Education, Guangzhou First People's Hospital, Guangzhou, China.
Department of Geriatric Neuroscience Center, Affiliated Brain Hospital, Guangzhou Medical University, Guangzhou, China.
Front Psychiatry. 2025 Feb 12;16:1491410. doi: 10.3389/fpsyt.2025.1491410. eCollection 2025.
Approximately one-third of depressed individuals receive treatment globally. The application rate of traditional Chinese medicine (TCM) for treating depression globally remains relatively low. The proposed study presents a pilot trial to evaluate the effectiveness of interventions at different levels in improving depression status in community populations.
A randomized controlled trial will be conducted in two communities in Guangdong, China, with a follow-up period of 12 weeks. Participants will be randomly allocated to control or intervention groups. Participants in the control group will be assigned to routine care, while participants in the intervention group will receive TCM intervention measures. The participants in the intervention group will receive integrated traditional Chinese and Western treatment according to the symptom grading of depression severity. Primary outcome measurements include the Patient Health Questionnaire (PHQ-9), the Hamilton Depression Rating Scale (HAMD-17), and the Self-Rating Depression Scale (SDS). Secondary outcome measurements include the Athens Insomnia Scale (AIS), the Epworth Sleepiness Scale (ESS), the Multiple Mental Health Literacy Scale (MMHL), the Short-Form 12 (SF-12), and the Treatment Emergent Symptom Scale (TESS). The data will be collected at baseline (T1), 2 weeks after intervention (T2), 4 weeks after intervention (T3), 8 weeks after intervention (T4), and 12 weeks after intervention (T5).
This study will provide an experimental basis for the effectiveness of hierarchical integrated traditional Chinese and Western medicine (ITCWM) in improving the condition of patients with different degrees of depression. At the end of the study, it is expected for the experimental group to have an improvement in depressive symptoms and sleep quality and an enhancement in mental health awareness.
http://www.chictr.org.cn, identifier ChiCTR2300075169.
全球约三分之一的抑郁症患者接受治疗。全球范围内,中医治疗抑郁症的应用率仍然相对较低。本拟开展的研究进行一项试点试验,以评估不同层面干预措施对改善社区人群抑郁状态的有效性。
将在中国广东的两个社区进行一项随机对照试验,随访期为12周。参与者将被随机分配到对照组或干预组。对照组参与者将接受常规护理,而干预组参与者将接受中医干预措施。干预组参与者将根据抑郁严重程度的症状分级接受中西医结合治疗。主要结局指标包括患者健康问卷(PHQ-9)、汉密尔顿抑郁量表(HAMD-17)和自评抑郁量表(SDS)。次要结局指标包括雅典失眠量表(AIS)、爱泼沃斯思睡量表(ESS)、多元心理健康素养量表(MMHL)、简明健康调查量表(SF-12)和治疗中出现的症状量表(TESS)。数据将在基线(T1)、干预后2周(T2)、干预后4周(T3)、干预后8周(T4)和干预后12周(T5)收集。
本研究将为分层中西医结合(ITCWM)改善不同程度抑郁症患者病情的有效性提供实验依据。在研究结束时,预计实验组的抑郁症状和睡眠质量会有所改善,心理健康意识会有所增强。